EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome

Juan Guerrero-Mauvecin iD, Natalia Villar-Gómez, Lucia Miño-Izquierdo, Adrián Povo-Retana, Adrian M Ramos, Gema Ruiz-Hurtado iD, Maria D Sanchez-Niño iD, Alberto Ortiz iD, Ana B Sanz iD

Antioxidants · 09.06.2025 · 14 (6) · 701

DOI: 10.3390/antiox14060701 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 09.06.2025. Verfasst von Juan Guerrero-Mauvecin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, 28040 …. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituo de Salud carlos III, Instituto de Salud Carlos III (ISCIII), European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cardiovascular–kidney–metabolic (CKM) syndrome was recently conceptualized to provide a holistic framework for diagnosing and treating the full spectrum of key age-associated interrelated conditions: overweight/obesity, type 2 diabetes mellitus, acute and chronic kidney disease, and cardiovascular disease. This conceptualization resulted from epidemiological associations, advances in our understanding of shared and interrelated pathogenic mechanisms, and observations that several drug families improved outcomes in all three components of CKM. Sodium/glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) enhance all CKM spectrum components, although their efficacy varies against specific components. However, the modified mechanisms by these drugs beyond glycemic control in CKM syndrome are poorly understood. We now deeply review the available literature regarding the impact of SGLT2i on oxidative stress and antioxidant defenses in preclinical and clinical studies of type 2 diabetes mellitus, acute and chronic kidney disease, cardiovascular disease, and CKM syndrome. Evidence suggests that SGLT2i may have a secondary antioxidant effect that reduces the vicious cycle of tissue injury—inflammation—tissue injury, even in organs distant from the primary injury.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorsacute kidney injuryantioxidant defensescardiovascular–kidney–metabolic syndromechronic kidney diseaseoxidative stresstreatment

Autor:innen und Institutionen

  • Laboratorio de Nefrología Experimental, Instituto de Investigación Sanitaria-Fundacion Jimenez Diaz (IIS-FJD), Universidad Autonoma de Madrid, 28040 Madrid, Spain.
  • Departamento de Enfermedades Metabólicas e Inmunitarias, Instituto de Investigaciones Biomédicas "Sols-Morreale", 28029 Madrid, Spain.
  • Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares CIBERCV, Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • RICORS2040, Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Cardiorenal Translational Laboratory, Imas12 Research Institute, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain.
  • Department of Physiology, School of Medicine, Universidad Autonoma de Madrid, 28029 Madrid, Spain.

ORCID-Profile: Juan Guerrero-Mauvecin, Gema Ruiz-Hurtado, Maria D Sanchez-Niño, Alberto Ortiz, Ana B Sanz

Förderung

  • Instituo de Salud carlos III
  • Instituto de Salud Carlos III (ISCIII)
  • European Union
  • COST (European Cooperation in Science and Technology)
  • European Health and Digital Executive Agency
  • Ministerio de Ciencia, Innovación y Universidades and Agencia Estatal de Investigación (MICIU)

Zitieren

APA

Guerrero-Mauvecin, J., Villar-Gómez, N., Miño-Izquierdo, L., Povo-Retana, A., Ramos, A. M., Ruiz-Hurtado, G., Sanchez-Niño, M. D., Ortiz, A., & Sanz, A. B. (2025). Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome. Antioxidants, 14(6), 701. https://doi.org/10.3390/antiox14060701

Vancouver

Guerrero-Mauvecin J, Villar-Gómez N, Miño-Izquierdo L, Povo-Retana A, Ramos AM, Ruiz-Hurtado G, et al. Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome. Antioxidants. 2025;14(6):701. doi:10.3390/antiox14060701

BibTeX
@article{GuerreroMauvecin2025,
  author = {Guerrero-Mauvecin, Juan and Villar-Gómez, Natalia and Miño-Izquierdo, Lucia and Povo-Retana, Adrián and Ramos, Adrian M and Ruiz-Hurtado, Gema and Sanchez-Niño, Maria D and Ortiz, Alberto and Sanz, Ana B},
  title = {Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome},
  journal = {Antioxidants},
  year = {2025},
  volume = {14},
  number = {6},
  pages = {701},
  doi = {10.3390/antiox14060701}
}
Kostenlos starten →